Management of Traumatic Brain Injury with Hypertonic Saline and Mannitol

Comparative Efficacy for ICP Reduction

Both 3% hypertonic saline and mannitol are equally effective at reducing intracranial pressure at equiosmotic doses, but hypertonic saline offers practical advantages including longer duration of effect, shorter ICU stays, and better maintenance of cerebral perfusion without causing hypovolemia 1, 2
At equiosmotic doses, mannitol and hypertonic saline demonstrate comparable efficacy in treating intracranial hypertension 1, 2
Mannitol is the only therapy among ICP-lowering treatments associated with improved cerebral oxygenation 1, 2

7.5% hypertonic saline at 250 mL per bolus administered over 15-20 minutes is the recommended concentration and dose 3
Target serum sodium concentration of 145-155 mmol/L 3
20% mannitol at 0.25-0.5 g/kg IV over 20 minutes, repeated every 6 hours as needed 4
Equiosmotic dose is approximately 250 mOsm 1, 2
Maximum daily dose of 2 g/kg to avoid adverse effects 4

Mannitol induces significant osmotic diuresis requiring volume compensation 1, 2
Mannitol may lead to hypotension 4
Serum osmolality must remain below 320 mOsm/L 4
Hypertonic saline exposes patients to hypernatremia and hyperchloremia 1, 2
Serum sodium should be measured within 6 hours of bolus administration 3
Avoid sodium levels exceeding 155-160 mmol/L 3

Choose hypertonic saline when hypovolemia or hypotension is present or a concern 4
Choose mannitol when hypernatremia is already present 4
Choose mannitol when improved cerebral oxygenation is the priority 1, 2
Both agents require monitoring of fluid, sodium, and chloride balances 1, 2
Both agents should only be used for documented intracranial hypertension, not prophylactically 1, 2

Prophylactic administration of hypertonic saline to patients without evidence of intracranial hypertension is not superior to crystalloids 1
Neither agent has proven benefit for improving neurological outcomes or survival despite effectiveness in reducing ICP 3
Hypertonic saline is not recommended for volume resuscitation in hemorrhagic shock 3
Both agents are temporizing measures before definitive treatment such as decompressive craniectomy 4
Despite intensive medical management with either agent, mortality in patients with increased ICP remains high (50-70%) 4